Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330252 · ClinicalTrials.gov registry record · Phase 1
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00330252 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 29 participants.
The verdict
NCT00330252, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of alemtuzumab and rituximab is safe and effective in treating patients with relapsed Chronic Lymphocytic Leukemia (CLL) and to determine whether alemtuzumab can be given as a single weekly subcutaneous dose, together with rituximab.
Interventions
- DRUG Alemtuzumab
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-05 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330252
The ClinicalTrials.gov registry entry for NCT00330252 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alemtuzumab is the first listed.
NCT00330252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00330252 about?
NCT00330252 is a clinical study titled "Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL". The purpose of this study is to determine whether the combination of alemtuzumab and rituximab is safe and effective in treating patients with relapsed Chronic Lymphocytic Leukemia (CLL) and to determine whether alemtuzumab can be given as a single weekly subcutaneous dose, together with rituximab.
What is the current status of trial NCT00330252?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2006-05. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00330252?
The interventions under investigation include: Alemtuzumab (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT00330252?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.